Imatinib inhibits migration of normal human epidermal melanocytes and suppress the phosphorylation of C-kit

Authors

  • Jian-Xin Xia Department of Dermatology, Second Affiliated Hospital of Jilin University, Changchun 130041
  • Fu-Qiu Li Department of Dermatology, Second Affiliated Hospital of Jilin University, Changchun 130041
  • Kazunori Urabe Department of Dermatology, School of Medicine of Kyushu University, Kyushu
  • Jin-Feng Wang Department of Dermatology, Second Affiliated Hospital of Jilin University, Changchun 130041
  • Masutaka Furue Department of Dermatology, School of Medicine of Kyushu University, Kyushu

DOI:

https://doi.org/10.3329/bjp.v7i2.10800

Keywords:

C-kit, Human epidermal melanocyte, Imatinib, Migration, Phosphorylation

Abstract

To investigate the inhibitory effect of imatinib on the migration of normal human epidermal melanocytes (NHEM), the growth and differentiation of NHEM were measured by MTT assay. Transwell Cell Migration Assay was performed to determine the migration of NHEM following imatinib treatment. The phosphorylation of c-kit in NHEM after imatinib treatment was measured by western blot assay. Imatinib at 0.1 ?M, 1.0 ?M and 5.0 ?M could inhibit the SCF (50 ng/mL) induced NHEM migration and suppress the phosphorylation of c-kit in NHEM. The result concluded that imatinib can inhibit SCF induced NHEM migration and suppress the c-kit phosphorylation in NHEM. This provide theoretical basis for the prevention of post-treatment recurrence of nevus spilus.

Downloads

Download data is not yet available.
Abstract
984
Download
610 Read
177

References

Bergamaschi O, Kon S, Doine AI, Ruben MP. Melanin repigmentation after gingivectomy: A 5-year clinical and transmission electron microscopic study in humans. Int J Periodontics Restorative Dent. 1993; 113: 85-92.

Cario-André M, Ardilouze L, Pain C, Gauthier Y, Mahon FX, Taieb A. Imatinib mesilate inhibits melanogenesis in vitro. Br J Dermatol. 2006; 155: 493-94.

Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997; 90: 3691-98.

Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996; 2: 561-66.

Grevelink JM, van Leeuwen RL, Anderson RR, Byers HR. Clinical and histological responses of congenital melanocytic nevi after single treatment with Q-switched lasers. Arch Dermatol. 1997; 133: 349-53.

Halaban R. The regulation of normal melanocyte proliferation. Pigment Cell Res. 2000; 13: 4-14.

Kawakami T, Soma Y, Kawa Y, Ito M, Yamasaki E, Watabe H, Hosaka E, Yajima K, Ohsumi K, Mizoguchi M. Transforming growth factor beta1 regulates melanocyte proliferation and differentiation in mouse neural crest cells via stem cell factor/KIT signaling. J Invest Dermatol. 2002; 118: 471-78.

Soria A, Cario-André M, Lepreux S, Rezvani HR, Pasquet JM, Pain C, Schaeverbeke T, Mahon FX, Taïeb A. The effect of glivec (imatinib) on scleroderma and normal dermal fibroblasts: A preclinical study. Dermatology 2008; 216: 109-17.

Downloads

Additional Files

Published

2012-06-09

How to Cite

Xia, J.-X., F.-Q. Li, K. Urabe, J.-F. Wang, and M. Furue. “Imatinib Inhibits Migration of Normal Human Epidermal Melanocytes and Suppress the Phosphorylation of C-Kit”. Bangladesh Journal of Pharmacology, vol. 7, no. 2, June 2012, pp. 100-3, doi:10.3329/bjp.v7i2.10800.

Issue

Vol. 7 No. 2 (2012)

Section

Research Articles

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).